Clinical Trials Logo

Heart Graft Dysfunction clinical trials

View clinical trials related to Heart Graft Dysfunction.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02013037 Completed - Clinical trials for Left Ventricular Dysfunction

The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation

DUET
Start date: November 2012
Phase: Phase 3
Study type: Interventional

All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen. The mechanism of an antibody is to attack an antigen. In antibody mediated rejection, antibodies will attack the transplanted heart, causing injury to the heart. The purpose of this investigation is to determine if a study drug, called eculizumab (Soliris), is safe to use in heart transplant recipients, and determine if it reduces risk of antibody-mediated rejection.